Global Drug Delivery in Cancer Market Size, Share, and Trends Analysis - Forecast to 2036 | Market to Reach USD 141.8 Billion as ADCs, Lipid Nanoparticles, and Asia-Pacific Drive 11.6% CAGR

Dublin, Oct. 19, 2026 -- "Drug Delivery in Cancer Market Size, Share & Trends Analysis, - Global Forecast to 2036" has been added to ResearchAndMarkets.com's offering.

The global drug delivery in cancer market is estimated at USD 47.3 billion in 2026 and is projected to reach USD 141.8 billion by 2036, expanding at a CAGR of 11.6% during the forecast period. The report examines market trends, technological advancements, clinical developments, regulatory conditions, competitive strategies, and growth opportunities across oncology therapeutics and advanced drug delivery platforms.

Market expansion is being driven by the rising global cancer burden, increasing demand for targeted oncology treatments, expanding biologics pipelines, and continued investment in advanced formulation technologies. Antibody-drug conjugates, liposomal and lipid-based delivery systems, polymeric nanoparticles and micelles, drug-eluting embolic systems, infusion and injectable platforms, and implantable drug delivery systems are gaining adoption across breast, lung, colorectal, liver, prostate, and hematological cancers.

Market Dynamics

Growing cancer incidence and prevalence are increasing demand for delivery platforms that enhance therapeutic efficacy, reduce off-target toxicity, and support personalized treatment regimens. Greater clinical use of antibody-drug conjugates, localized therapies, controlled-release formulations, and subcutaneous administration is also improving patient convenience and reducing pressure on oncology treatment facilities.

Technological advances in bioconjugation, linker chemistry, lipid nanoparticles, polymer engineering, enzymatic subcutaneous delivery, catheter-based administration, and precision oncology are expanding the range of therapeutics that can be delivered to cancerous tissues. Biomarker-guided patient selection and integrated clinical development strategies are expected to strengthen treatment outcomes and commercial adoption.

Market growth may be constrained by complex manufacturing processes, high research and development costs, stringent regulatory requirements, limited production capacity, reimbursement barriers, formulation stability concerns, and specialized clinical expertise requirements. However, expanding oncology pipelines, increased biologics manufacturing capacity, and investment in outpatient and localized treatment models are creating substantial long-term opportunities.

Segment Insights

By technology, the market includes antibody-drug conjugates, liposomal and lipid-based delivery systems, polymeric nanoparticle and micellar systems, drug-eluting embolic systems, infusion and injectable delivery systems, implantable drug delivery systems, and other technologies. Antibody-drug conjugates account for the largest revenue share, supported by approvals across breast, lung, urothelial, and hematological cancer indications, label expansions, licensing agreements, and acquisitions. Liposomal and lipid-based delivery systems are expected to record the fastest growth due to expanding oncology pipelines and increased manufacturing investment by contract development and manufacturing organizations.

By route of administration, the report evaluates parenteral, oral, topical, and other delivery routes. Parenteral administration remains the largest segment because intravenous and subcutaneous delivery continue to dominate biologic and cytotoxic cancer treatment. Subcutaneous delivery is projected to grow rapidly as established intravenous regimens are reformulated to reduce infusion chair time, improve convenience, and increase treatment-center capacity.

By application, breast cancer represents the largest market segment, reflecting high global incidence and the availability of antibody-drug conjugates and liposomal formulations for HER2-positive and triple-negative breast cancer. Blood cancer is expected to register the fastest growth, driven by targeted delivery candidates for leukemia, lymphoma, and multiple myeloma.

Regional Outlook

North America holds the largest share of the global drug delivery in cancer market. Growth is supported by advanced oncology infrastructure, extensive clinical research, high treatment expenditure, strong regulatory capabilities, and the concentration of leading biopharmaceutical, medical device, and drug delivery technology companies in the U.S.

Europe continues to expand through established cancer care networks, pharmaceutical and biotechnology expertise, supportive regulatory systems, and specialized formulation and manufacturing capabilities. Asia-Pacific is projected to record the fastest growth, supported by increasing cancer incidence, higher healthcare expenditure, improving access to advanced therapies, and expanding biologics and biosimilar manufacturing in China, India, Japan, and South Korea. Latin America and the Middle East & Africa also offer emerging opportunities as specialized oncology infrastructure and access to advanced treatments improve.

Competitive Landscape

Competition is shaped by technology platform breadth, delivery precision, manufacturing scalability, clinical evidence, regulatory expertise, intellectual property, commercialization capabilities, and geographic reach. Companies are using partnerships, licensing agreements, acquisitions, manufacturing expansions, and research investments to advance antibody-drug conjugates, nanoparticle formulations, subcutaneous delivery platforms, drug-eluting embolic systems, and implantable technologies.

Key companies profiled include Daiichi Sankyo Company, Limited, AstraZeneca plc, Roche Holding AG, Pfizer Inc., Merck & Co., Inc., Bristol Myers Squibb Company, Johnson & Johnson, Gilead Sciences, Inc., AbbVie Inc., Novartis AG, Ipsen S.A., Halozyme Therapeutics, Inc., Boston Scientific Corporation, Terumo Corporation, Merit Medical Systems, Inc., and Catalent, Inc.

Strategic Value of the Report

• Provides global market size estimates and forecasts through 2036.
• Identifies high-growth opportunities by technology, route of administration, application, and region.
• Assesses clinical, regulatory, manufacturing, reimbursement, and investment trends.
• Benchmarks leading companies by technology portfolios, pipelines, capabilities, and competitive positioning.
• Supports product development, licensing, partnership evaluation, investment planning, market entry, and geographic expansion.
• Delivers actionable intelligence for biopharmaceutical companies, medical device manufacturers, healthcare providers, investors, distributors, and contract development and manufacturing organizations.

The report also addresses the factors influencing market growth, the segments expected to achieve the strongest performance, the geographic markets offering attractive commercial opportunities, and the strategies companies are adopting to strengthen their positions in the evolving oncology drug delivery market.

Key Topics Covered:

1. Introduction
1.1 Market Definition and Scope
1.2 Market Ecosystem
1.3 Currency and Limitations
1.3.1 Currency
1.3.2 Limitations
1.4 Key Stakeholders

2. Research Methodology
2.1 Research Approach
2.2 Data Collection & Validation Process
2.2.1 Secondary Research
2.2.2 Primary Research & Validation
2.2.2.1 Primary Interviews with Experts
2.2.2.2 Country-/Region-Level Analysis
2.3 Market Estimation
2.3.1 Bottom-Up Approach
2.3.2 Top-Down Approach
2.4 Data Triangulation
2.5 Assumptions for the Study

3. Executive Summary
3.1 Market Overview
3.2 Market Analysis by Technology
3.3 Market Analysis by Route of Administration
3.4 Market Analysis by Application
3.5 Market Analysis by Geography

4. Market Dynamics
4.1 Overview
4.2 Drivers
4.2.1 Rising Global Cancer Incidence Driving Sustained Demand for Targeted Delivery Technologies
4.2.2 Rapid Clinical and Commercial Expansion of Antibody Drug Conjugates Across Oncology Indications
4.2.3 Growing Adoption of Subcutaneous Delivery Technologies Reducing Infusion Center Burden
4.2.4 Established Clinical Use of Drug Eluting Embolic Systems in Liver Directed Cancer Therapy
4.3 Restraints
4.3.1 Complex and Costly Manufacturing Requirements for Biologic Conjugates and Nanoparticle Formulations
4.3.2 Limited Specialized Manufacturing Capacity Constraining Payload and Linker Supply
4.4 Opportunities
4.4.1 Expanding Lipid Nanoparticle and Liposomal Pipeline Broadening Deliverable Payload Options
4.4.2 Growing Biologics Manufacturing Capacity in Asia Pacific Opening New Regional Demand
4.4.3 Continued Conversion of Intravenous Biologic Regimens to Subcutaneous Formulations
4.5 Challenges
4.5.1 High Cost of Advanced Delivery Platforms Influencing Reimbursement and Market Access Timelines
4.5.2 Regulatory Complexity in Characterizing Novel Conjugate and Nanoparticle Formulations
4.6 Porter's Five Forces Analysis

5. Drug Delivery in Cancer Market, by Technology
5.1 Overview
5.2 Antibody Drug Conjugates
5.3 Liposomal and Lipid Based Delivery Systems
5.4 Polymeric Nanoparticle and Micellar Systems
5.5 Drug Eluting Embolic Systems
5.5.1 Microspheres
5.5.2 Drug Eluting Beads
5.6 Infusion and Injectable Delivery Systems
5.7 Implantable Drug Delivery Systems
5.8 Other Technologies

6. Drug Delivery in Cancer Market, by Route of Administration
6.1 Overview
6.2 Parenteral
6.2.1 Intravenous
6.2.2 Subcutaneous
6.2.3 Intra-arterial and Intratumoral
6.3 Oral
6.4 Topical
6.5 Other Routes of Administration

7. Drug Delivery in Cancer Market, by Application
7.1 Overview
7.2 Breast Cancer
7.3 Lung Cancer
7.4 Colorectal Cancer
7.5 Liver Cancer
7.6 Blood Cancer
7.6.1 Leukemia
7.6.2 Lymphoma
7.6.3 Multiple Myeloma
7.7 Prostate Cancer
7.8 Other Applications

8. Drug Delivery in Cancer Market, by Geography
8.1 Overview
8.2 North America
8.2.1 U.S.
8.2.2 Canada
8.3 Europe
8.3.1 Germany
8.3.2 U.K.
8.3.3 France
8.3.4 Italy
8.3.5 Spain
8.3.6 Switzerland
8.3.7 Rest of Europe
8.4 Asia Pacific
8.4.1 China
8.4.2 Japan
8.4.3 India
8.4.4 South Korea
8.4.5 Australia
8.4.6 Rest of Asia Pacific
8.5 Latin America
8.5.1 Brazil
8.5.2 Mexico
8.5.3 Rest of Latin America
8.6 Middle East and Africa
8.6.1 Saudi Arabia
8.6.2 UAE
8.6.3 South Africa
8.6.4 Rest of Middle East and Africa

9. Competitive Landscape
9.1 Overview
9.2 Key Growth Strategies
9.3 Competitive Benchmarking
9.4 Competitive Dashboard
9.4.1 Industry Leaders
9.4.2 Market Differentiators
9.4.3 Vanguards
9.4.4 Emerging Companies
9.5 Market Share/Ranking Analysis (2025)

10. Company Profiles
10.1 Daiichi Sankyo Company, Limited
10.2 AstraZeneca plc
10.3 Roche Holding AG (Genentech, Inc.)
10.4 Pfizer Inc.
10.5 Merck & Co., Inc.
10.6 Bristol Myers Squibb Company
10.7 Johnson & Johnson
10.8 Gilead Sciences, Inc.
10.9 AbbVie Inc.
10.10 Novartis AG
10.11 Ipsen S.A.
10.12 Halozyme Therapeutics, Inc.
10.13 Boston Scientific Corporation
10.14 Terumo Corporation
10.15 Merit Medical Systems, Inc.
10.16 Catalent, Inc.

11. Appendix
11.1 Questionnaire
11.2 Available Customization Options
11.3 Related Reports
For more information about this report visit https://www.researchandmarkets.com/r/2m4szb

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.